Company intelligence / Profile preview
Sanakin BioScience
- Ownership
- Private
- Development stage
- Other
Overview
Sanakin BioScience has developed and commercialized the "Sanakin Technology," which enables the production of an autologous cytokine-rich serum from a patient's own blood. This technology is used for regulating inflammation and stimulating tissue regeneration in both human medicine (orthopedics, dermatology) and veterinary medicine. The company reports over 300,000 applications worldwide with more than 1,600 doctors using their therapies across 40+ countries as of 2022. Clinical results are described as encouraging in terms of safety/tolerability and efficacy for reducing inflammation and promoting healing/regeneration.
- Therapeutic areas
- DermatologyRheumatologyOther
- Modalities
- Autologous serum therapyBiologic (autologous cytokine-rich serum)
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Sanakin BioScience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sanakin BioScience.